Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-21-039457
Filing Date
2021-10-06
Accepted
2021-10-06 16:15:57
Documents
1
Period of Report
2021-10-04

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 7782
  Complete submission text file 0000899243-21-039457.txt   9226
Mailing Address 3052 PACIFIC AVENUE SAN FRANCISCO CA 94115
Business Address
Tananbaum James B. (Reporting) CIK: 0001581754 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39438 | Film No.: 211309911

Mailing Address 300 ONE KENDALL SQUARE, 3RD FLOOR CAMBRIDGE MA 02139
Business Address 300 ONE KENDALL SQUARE, 3RD FLOOR CAMBRIDGE MA 02139 (617) 401-4400
Gemini Therapeutics, Inc. /DE (Issuer) CIK: 0001816736 (see all company filings)

EIN.: 851613057 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations